Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4142
Title: Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
Authors: Moore, Andrew 
Kunarajah, K.
Hennig, S.
Norris, R. L. G.
Lobb, M.
Charles, B. G.
Pinkerton, R.
Issue Date: 2017
Source: 80, (1), 2017, p. 15-25
Pages: 15-25
Journal: Cancer Chemotherapy and Pharmacology
Abstract: Purpose: Anthracyclines are a mainstay of the treatment of several childhood malignancies, but their utility is limited by dose-related cardiotoxicity. This study is aimed to explore the link between exposure of paediatric cancer patients to doxorubicin and its metabolite doxorubicinol, and cardiac troponin I (cTnI). Methods: In a prospective pilot study plasma doxorubicin, doxorubicinol, and cTnI concentrations were measured in samples from children undergoing cancer chemotherapy. A mixed-effects population pharmacokinetic model for doxorubicin and doxorubicinol and in combination with a turn-over model for cTnI were developed. Results: Seventeen patients, aged 3.4–14.7 year, treated for a variety of cancers had 99 doxorubicin and 119 doxorubicinol concentrations analysed from samples drawn between 0.5 and 336 h after the start of the infusion. Eleven patients had received previous doses of anthracyclines, with a median cumulative prior dose of 90 mg/m2 (range 0–225 mg/m2). The median administered doxorubicin dose was 30 mg/m2 (range 25–75 mg/m2). Doxorubicin disposition was described by a three-compartment model with first-order elimination and metabolism to doxorubicinol. Body surface area was related to all clearance and distribution parameters and age further influenced clearance (CL, 58.7 L/h/1.8 m2 for an average 8.4-year-old patient). Combined doxorubicin and metabolite exposure stimulated a temporary increase in cTnI in plasma, with a concentration of 11.8 µg/L required to achieve half-maximal effect. Prior cumulative anthracycline dosage received by patients was predictive of an increased cTnI baseline prior to a new doxorubicin dose. Conclusion: Prior anthracycline exposure increased baseline cTnI in a dose-dependent manner, consistent with the known cumulative risk of anthracycline exposure-induced cardiotoxicity.L6157025802017-05-02
2017-07-06
DOI: 10.1007/s00280-017-3309-6
Resources: https://www.embase.com/search/results?subaction=viewrecord&id=L615702580&from=exporthttp://dx.doi.org/10.1007/s00280-017-3309-6 |
Keywords: drug distribution;drug effect;drug elimination;drug exposure;drug metabolism;female;hepatoblastoma;Hodgkin disease;human;male;multiple cycle treatment;nephroblastoma;neuroblastoma;nonhodgkin lymphoma;osteosarcoma;pilot study;population;preschool child;priority journal;prospective study;school child;synovial sarcoma;turnover rate;anthracyclinedoxorubicin;doxorubicinol;troponin I;acute lymphoblastic leukemia;adolescent;article;body surface;cancer combination chemotherapy;cancer patient;cardiotoxicity;child;childhood cancer;clinical article;concentration response;disease association;distribution parameters;drug blood level;drug clearance;drug disposition
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

76
checked on Feb 14, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.